Zheng Quan Zhi Xing·2025-08-26 16:35Summary of Key Points Core Viewpoint - The company has renewed its product/service mutual supply framework agreement with Sinopharm Holdings, extending the agreement from January 1, 2026, to December 31, 2028, to support ongoing business needs [1][2]. Group Overview - The mutual supply framework agreement is essential for the company's operations, which span pharmaceutical manufacturing, medical devices, and healthcare services, creating a necessary and ongoing business relationship with Sinopharm Holdings [2][4]. Financial Data - The actual transactions between the company and Sinopharm Holdings for the years 2023, 2024, and the first half of 2025 are as follows: - Sales of raw materials or goods: 642,908,000 RMB in 2023, 557,908,000 RMB in 2024, and 292,003,000 RMB in the first half of 2025 - Purchases of raw materials or goods: 35,794,000 RMB in 2023, 45,187,000 RMB in 2024, and 21,991,000 RMB in the first half of 2025 - Provision of services: 93,000 RMB in 2023, 49,000 RMB in 2024, and 4,000 RMB in the first half of 2025 - Acceptance of services: 427,000 RMB in 2023, 179,000 RMB in 2024, and 121,000 RMB in the first half of 2025 [3][4]. Expected Transaction Limits - The expected transaction limits under the new framework agreement are as follows: - Sales of raw materials or goods: 1,100,000,000 RMB for 2026, 1,300,000,000 RMB for 2027, and 1,500,000,000 RMB for 2028 - Purchases of raw materials or goods: 80,000,000 RMB for 2026, 100,000,000 RMB for 2027, and 120,000,000 RMB for 2028 - Provision of services: 100,000 RMB for 2026, 120,000 RMB for 2027, and 150,000 RMB for 2028 - Acceptance of services: 2,000,000 RMB for 2026, 2,500,000 RMB for 2027, and 3,000,000 RMB for 2028 [4][5]. Approval Process - The renewal of the framework agreement requires approval from the company's shareholders after being reviewed and approved by the board of directors, excluding related directors [5][9].